留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

索拉菲尼与异硫氰酸4-(甲基亚磺酰)丁酯体外协同杀伤肝癌细胞实验研究

何文婷,  巩志荣,  孙治国,  王美平,  高洁,  钟延强,  鲁莹

downloadPDF
文章导航 > 药学实践与服务  > 2015 >  33(2): 138-142
何文婷, 巩志荣, 孙治国, 王美平, 高洁, 钟延强, 鲁莹. 索拉菲尼与异硫氰酸4-(甲基亚磺酰)丁酯体外协同杀伤肝癌细胞实验研究[J]. 药学实践与服务, 2015, 33(2): 138-142. doi: 10.3969/j.issn.1006-0111.2015.02.012
引用本文: 何文婷, 巩志荣, 孙治国, 王美平, 高洁, 钟延强, 鲁莹. 索拉菲尼与异硫氰酸4-(甲基亚磺酰)丁酯体外协同杀伤肝癌细胞实验研究[J]. 药学实践与服务, 2015, 33(2): 138-142. doi: 10.3969/j.issn.1006-0111.2015.02.012
shu
HE Wenting, GONG Zhirong, SUN Zhiguo, WANG Meiping, GAO Jie, ZHONG Yanqiang, LU Ying. Synergic effects of sorafenib combined with sulforaphane against hepatocellular carcinoma cells in vitro[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(2): 138-142. doi: 10.3969/j.issn.1006-0111.2015.02.012
Citation: HE Wenting, GONG Zhirong, SUN Zhiguo, WANG Meiping, GAO Jie, ZHONG Yanqiang, LU Ying. Synergic effects of sorafenib combined with sulforaphane against hepatocellular carcinoma cells in vitro[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(2): 138-142. doi: 10.3969/j.issn.1006-0111.2015.02.012
shu

索拉菲尼与异硫氰酸4-(甲基亚磺酰)丁酯体外协同杀伤肝癌细胞实验研究

doi: 10.3969/j.issn.1006-0111.2015.02.012
  • 1.

    福建中医药大学药学系, 福建 福州 350108

  • 2.

    第二军医大学药学院, 上海 200433

  • 3.

    福建中医药大学药学系, 福建 福州 350108;第二军医大学药学院, 上海 200433

Synergic effects of sorafenib combined with sulforaphane against hepatocellular carcinoma cells in vitro

  • 1.

    Department of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350108, China

  • 2.

    Department of Pharmaceutics, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

  • 3.

    Department of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350108, China;Department of Pharmaceutics, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

  • 摘要: 目的 探讨索拉菲尼(sorafenib,SO)联合异硫氰酸4-(甲基亚磺酰)丁酯(sulforaphane,SF)杀伤肝癌细胞HepG2的协同比例。 方法 采用CCK-8法探讨SO和SF对HepG2杀伤效果最强的协同比例,利用协同指数(CI)反映协同杀伤效应:CI>1.1为拮抗;0.9结果 CCK-8法显示:SO与SF在摩尔比为1:1、1:10、1:20时,为拮抗作用(CI>1.1);在10:1时,为相加作用(0.9P<0.01),早期和晚期凋亡率(21.71±6.06)%显著高于拮抗比例1:1的凋亡率(6.64±0.31)%(P<0.01)。 结论 SO和SF摩尔比为5:1时能达到协同杀伤HepG2肝癌细胞的效果。
    Abstract: Objective To investigate the synergic ratio of sorafenib (SO) and sulforaphane (SF) against the hepatocellular carcinoma cell line HepG2 in vitro. Methods The synergic effect of SO combined with SF against HepG2 cells was determined by the CCK8 assay (the synergic effect was determined by combination index (CI) value: CI>1.1, antagonistic; 0.9Results The CCK-8 assay showed that SO combined with SF at the molar rate of 1:1,1:10 and 1:20 exhibited strong antagonism (CI>1.1), whereas 20:1,5:1 and 1:5 ratio resulted in synergistic activity (CI<0.9). Furthermore, 10:1 ratio acted as an additive effective (0.9P<0.01). The early and late apoptosis rate of HepG2 cells (21.71±6.06) of the group treated with SO combined with SF at 5:1 synergistic ratio was significantly higher than that of the group treated with SO combined with SF at 1:1 antagonistic ratio(6.64±0.311)(P<0.01). Conclusion SO combined with SF at the molar rate of 5:1 can synergistically inhibit the growth of hepatocellular carcinoma cell line HepG2 in vitro.
  • [1] Wilhelm SM,Adnane L,Newell P,et al.Preclinical over view of sorafenib,a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling[J].Mol Cancer Ther,2008,7(10):3129 3140.
    [2] Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis[J].Cancer Cell,2009,15(3):220 231.
    [3] Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis[J]. Cancer Cell,2009,15(3):232 239.
    [4] Rausch V, Lui L, Kallifatidis G, et al. Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics[J]. Cancer Res,2010,70(12):5004-5013.
    [5] Choi S, Lew KL, Xiao H, et al. D,L-Sulforaphane-induced cell death in human prostate cancer cells is regulated by inhibitor of apoptosis family proteins and Apaf-1[J]. Carcinogenesis,2007,28(1):151 162.
    [6] Xu C, Shen G, Chen C, et al. Suppression of NF-kappaB and NF-kappaB-regulated gene expression by sulforaphane and PEITC through IkappaBalpha, IKK pathway in human prostate cancer PC-3 cells[J]. Oncogene,2005,24(28):4486-4495.
    [7] Jeong WS, Kim IW, Hu R,et al. Modulatory properties of various natural chemopreventive agents on the activation of NF-kappaB signaling pathway[J]. Pharm Res,2004,21(4):661 670.
    [8] Tardi P, Johnstone S, Harasym N,et al. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy[J].Leuk Res,2009,33(1):129-139.
    [9] Kupsch P, Henning B, Passarge K, et al. Results of a phase Ⅰ trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer[J]. Clin Colorectal Cancer, 2005,5(3):188-196.
    [10] Lee J, Kang WK, Kwon JM, et al.Phase Ⅱ trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.[J].Ann Oncol,2007,18(1):88-92.
    [11] Richly H, Henning B, Kupsch P, et al. Results of a phase Ⅰ trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors[J]. Ann Oncol,2006,17(5):866 873.
    [12] Jonge MJA, Dumez H,Kitzen JEM, et al. Phase Ⅰ safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours[J].Eur J Cancer,2011,47(9):1328-1335.
    [13] Flaherty KT, Lee SJ, Zhao F, et al.Phase Ⅲ trial of carboplatin and paclitacel with or without sorafenib in metastatic melanoma[J].J Clin Oncol,2013,31(3):373-379.
    [14] Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[J].Cancer Res,2004,64(19):7099-7109.
    [15] Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants[J]. J Natl Cancer Inst, 2006,98(5):326-334.
    [16] Clarke JD, Dashwood RH, Ho E. Multi-targeted prevention of cancer by sulforaphane[J].Cancer Lett, 2008,269(2):291-304.
    [17] Zhang Y, Tang L. Discovery and development of sulforaphane as a cancer chemopreventive phytochemical[J].Acta Pharmacol Sin, 2007,28(9):1343-1354.
    [18] Pavillard V, Kherfellah D, Richard S, et al. Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants[J].Br J Cancer, 2001,85(7):1077-1083.
  • [1] 朱鑫宇, 白浩然, 赵娜萍, 戚大川, 卫立辛, 张黎.  基于网络药理学探明八宝丹调控原发性肝癌的潜在机制研究 . 药学实践与服务, 2024, 42(4): 157-164. doi: 10.12206/j.issn.2097-2024.202401061
    [2] 何亚伦, 祁智, 常杰.  消胀通便膏在晚期肝癌患者阿片类药物相关性便秘的应用研究 . 药学实践与服务, 2024, 42(): 1-4. doi: 10.12206/j.issn.2097-2024.202309009
    [3] 钟志鹏, 郭冰洁, 肖楚兰, 殷子斐, 李柏.  基于数据挖掘的中医药治疗TACE术后栓塞综合征用药规律研究 . 药学实践与服务, 2023, 41(12): 747-752, 759. doi: 10.12206/j.issn.2097-2024.202208101
    [4] 徐圣弢, 吴琼, 刘佃花, 王琳召, 谭蔚锋, 陈俊.  基于中心碳代谢分析技术的肝胆系统疾病靶向代谢组学研究 . 药学实践与服务, 2023, 41(12): 753-759. doi: 10.12206/j.issn.2097-2024.202302040
    [5] 李婷婷, 张俊平.  信号转导和转录激活因子3在肝病中的研究进展 . 药学实践与服务, 2022, 40(3): 208-212, 280. doi: 10.12206/j.issn.1006-0111.202109072
    [6] 林辉, 杨远, 王志红, 林川, 周伟平.  帕瑞昔布钠在肝癌肝切除术后的应用 . 药学实践与服务, 2017, 35(1): 73-74,81. doi: 10.3969/j.issn.1006-0111.2017.01.018
    [7] 单兴杰, 闫占宽, 于超峰, 李传筠.  索拉非尼固体分散体的制备及性质研究 . 药学实践与服务, 2016, 34(4): 320-323,342. doi: 10.3969/j.issn.1006-0111.2016.04.009
    [8] 战旗, 李悦悦, 王晓俊, 陈安妮, 顾苏利, 张国庆.  人血白蛋白在原发性肝癌肝切除术后的应用分析 . 药学实践与服务, 2015, 33(5): 463-466. doi: 10.3969/j.issn.1006-0111.2015.05.023
    [9] 吕磊, 赵亮, 兰红涛, 金柔男, 张国庆.  应用HPLC-MS技术测定健康受试者和肝癌患者血浆中13种胆汁酸的含量 . 药学实践与服务, 2014, 32(4): 270-272,293. doi: 10.3969/j.issn.1006-0111.2014.04.008
    [10] 金柔男, 李乐乐, 龚纯贵.  肝癌切除术后口服UDCA血清胆汁酸浓度变化情况分析 . 药学实践与服务, 2013, 31(1): 45-48. doi: 10.3969/j.issn.1006-0111.2013.01.013
    [11] 刘悦, 赵亮, 李燕, 朱臻宇, 柴逸峰.  肝细胞性肝癌代谢组学研究进展 . 药学实践与服务, 2013, 31(2): 81-85. doi: 10.3969/j.issn.1006-0111.2013.02.001
    [12] 陈子安, 雷招宝.  埃索美拉唑的不良反应与合理用药 . 药学实践与服务, 2010, 28(6): 468-470.
    [13] 战旗, 顾大伟, 徐丽丽, 陈俊, 范立青, 龚纯贵.  原发性肝癌患者介入治疗感染及抗菌药物应用分析 . 药学实践与服务, 2010, 28(2): 142-145.
    [14] 刘娜, 吕加国, 周有骏, 朱驹.  L-2-(N-叔丁氧酰基)-3′,4′-二甲氧基苯丙氨酸乙酯的合成 . 药学实践与服务, 2009, 27(6): 445-447.
    [15] 贾静, 李悦悦, 朱臻宇, 柴逸峰, 张国庆.  3种常用抗癌药物对人肝癌细胞HepG2抑制作用的研究 . 药学实践与服务, 2009, 27(5): 323-333,361.
    [16] 戴德银.  肝癌用药的一些新进展 . 药学实践与服务, 1993, (1): 36-38.
    [17] 洪永福.  国产小扁豆凝集素用于诊断早期肝癌 . 药学实践与服务, 1991, (4): 96-96.
    [18] 康雪莱.  异搏定和奎尼丁 . 药学实践与服务, 1988, (3): 37-38.
    [19] 周林.  抗肝癌新药绿舒筋投入临床验证阶段 . 药学实践与服务, 1986, (3): 78-78.
    [20] 苏开仲, 魏文树.  地高辛与奎尼丁 . 药学实践与服务, 1985, (2): 57-57.
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  2525
  • HTML全文浏览量:  139
  • PDF下载量:  418
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-09-28
  • 修回日期:  2014-12-26

索拉菲尼与异硫氰酸4-(甲基亚磺酰)丁酯体外协同杀伤肝癌细胞实验研究

doi: 10.3969/j.issn.1006-0111.2015.02.012
  • 1. 福建中医药大学药学系, 福建 福州 350108
  • 2. 第二军医大学药学院, 上海 200433
  • 3. 福建中医药大学药学系, 福建 福州 350108;第二军医大学药学院, 上海 200433
  • 收稿日期: 2014-09-28
  • 修回日期: 2014-12-26

摘要: 目的 探讨索拉菲尼(sorafenib,SO)联合异硫氰酸4-(甲基亚磺酰)丁酯(sulforaphane,SF)杀伤肝癌细胞HepG2的协同比例。 方法 采用CCK-8法探讨SO和SF对HepG2杀伤效果最强的协同比例,利用协同指数(CI)反映协同杀伤效应:CI>1.1为拮抗;0.9结果 CCK-8法显示:SO与SF在摩尔比为1:1、1:10、1:20时,为拮抗作用(CI>1.1);在10:1时,为相加作用(0.9P<0.01),早期和晚期凋亡率(21.71±6.06)%显著高于拮抗比例1:1的凋亡率(6.64±0.31)%(P<0.01)。 结论 SO和SF摩尔比为5:1时能达到协同杀伤HepG2肝癌细胞的效果。

English Abstract

何文婷, 巩志荣, 孙治国, 王美平, 高洁, 钟延强, 鲁莹. 索拉菲尼与异硫氰酸4-(甲基亚磺酰)丁酯体外协同杀伤肝癌细胞实验研究[J]. 药学实践与服务, 2015, 33(2): 138-142. doi: 10.3969/j.issn.1006-0111.2015.02.012
引用本文: 何文婷, 巩志荣, 孙治国, 王美平, 高洁, 钟延强, 鲁莹. 索拉菲尼与异硫氰酸4-(甲基亚磺酰)丁酯体外协同杀伤肝癌细胞实验研究[J]. 药学实践与服务, 2015, 33(2): 138-142. doi: 10.3969/j.issn.1006-0111.2015.02.012
shu
HE Wenting, GONG Zhirong, SUN Zhiguo, WANG Meiping, GAO Jie, ZHONG Yanqiang, LU Ying. Synergic effects of sorafenib combined with sulforaphane against hepatocellular carcinoma cells in vitro[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(2): 138-142. doi: 10.3969/j.issn.1006-0111.2015.02.012
Citation: HE Wenting, GONG Zhirong, SUN Zhiguo, WANG Meiping, GAO Jie, ZHONG Yanqiang, LU Ying. Synergic effects of sorafenib combined with sulforaphane against hepatocellular carcinoma cells in vitro[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(2): 138-142. doi: 10.3969/j.issn.1006-0111.2015.02.012
shu

    全文HTML

参考文献 (18)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计